Real-World Study on Emotional and Social Effects of Antifibrotic Therapy in Patients with Idiopathic or Progressive Pulmonary Fibrosis in Japan

What this Trial Is About

This observational study is conducted across Japan to explore the emotional and social experiences of patients with Idiopathic Pulmonary Fibrosis IPF or Progressive Pulmonary Fibrosis PPF who are receiving antifibrotic treatments. The research aims to understand how patients feel about the side effects of these treatments and how their attitudes relate to individual characteristics. The study is sponsored by Boehringer Ingelheim and uses a cross-sectional design. Participants include Japanese patients with IPF or PPF who have recently used antifibrotic drugs such as nintedanib or pirfenidone. The study collects data through a single online patient-reported outcome questionnaire that takes approximately 20 minutes to complete. There are no treatment interventions or comparator groups since it is an observational survey. During the study, participants will complete the survey once, providing information on their experiences with side effects, quality of life, and decision-making related to treatment. Researchers will analyze scores from several questionnaires including the PESaM side effects sub-domain, EQ-5D-5L, and SDM-Q-9. The outcomes focus on emotional and social impacts related to treatment side effects. The study involves no further follow-up, and participation is limited to the time needed to complete the survey.

Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World Study